Akash Maniam, Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared on LinkedIn:
“Historic moment for all those involved in managing breast cancer in the UK.
As a breast oncologist, I couldn’t be happier to finally be able to use the most powerful tool available in treating HER2-low disease.
Outstanding advocacy by patients, phycisians and indeed all stakeholders involved.
Great decision by NICE. The paradigm shifts even further now.”
You might be interested in:
